Galit_Alter

Galit Alter

Galit Alter

Immunologist and virologist


Galit Alter is an immunologist and virologist, professor of medicine at Harvard Medical School, and group leader at the Ragon Institute of MGH, MIT and Harvard. She is known for her work on the expansion of particular natural killer cell subtypes in response to HIV-1 infection.[4][5] She has also contributed to the understanding of how SARS-CoV-2 antibody titers correlate with sustained humoral protection, including identifying coordinated immune cell-antibody signatures that may predict COVID-19 infection outcome.[1][6]

Quick Facts Born, Education ...

In October 2022 she became Vice President of Immunology in Infectious Disease Research at Moderna[7]


References

  1. Scanlon, Jessie (2020-12-10). "Galit Alter: Connecting scientists to speed up the COVID-19 fight". bostonglobe.com. Retrieved 2021-02-23.
  2. Alter, Galit; Malenfant, Jessica M; Altfeld, Marcus (2004). "CD107a as a functional marker for the identification of natural killer cell activity". J Immunol Methods. 294 (1–2): 15–22. doi:10.1016/j.jim.2004.08.008. PMID 15604012. Retrieved 1 April 2021.
  3. Atyeo, Caroline; Fischinger, Stephanie; Zohar, Tomer...; Alter, Galit (15 September 2020). "Distinct Early Serological Signatures Track with SARS-CoV-2 Survival". Immunity. 53 (3): 524–532. doi:10.1016/j.immuni.2020.07.020. PMC 7392190. PMID 32783920.

Share this article:

This article uses material from the Wikipedia article Galit_Alter, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.